Phase 1b Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase of Trial: Phase I
Latest Information Update: 03 Aug 2018
At a glance
- Drugs Alvocidib (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 08 Jun 2018 Planned End Date changed from 24 Mar 2021 to 21 May 2021.
- 08 Jun 2018 Status changed from not yet recruiting to recruiting.
- 27 Feb 2018 New trial record